Recently published research from Business Monitor International, "Thailand Pharmaceuticals & Healthcare Report Q4 2012", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 12/22/2012 -- BMI View: Over the medium to long term, Thailand will be facing intensive competition from neighbouring countries such as Malaysia, Indonesia and Philippines as they roll out plans to improve healthcare coverage and boost growth in the pharmaceutical industry. The intense competition coupled with the usage of compulsory licenses, regulatory lapses and widespread corruption will deter foreign investments into the sector. Despite this we highlight that the country's strong medical tourism sector and the impending implementation of the ASEAN Economic Committee will continue to attract private healthcare providers (and the related sub-sectors) into the country.
Headline Expenditure Projections
- Pharmaceuticals: THB130.95bn (US$4.41bn) in 2011 to THB136.16bn (US$4.18bn) in 2012; +3.98% in local currency terms and -5.2% in US dollar terms. Forecast unchanged from Q312.
- Healthcare: THB410.20bn (US$13.46bn) in 2011 to THB425.32bn (US$13.05bn) in 2012; +4.9% in local currency terms and -1.9% in US dollar terms. Forecast broadly unchanged from Q312.
- Medical devices: THB33.88bn (US$1.11bn) in 2011 to THB38.95bn (US$1.20bn) in 2012; +15% in local currency terms and 7.5% in US dollar terms. Forecast upgraded due to receipt of new historic data.
View Full Report Details and Table of Contents
Business Environment Rating: Thailand's Pharmaceuticals Risk/Reward Ratings (RRRs) is maintained at 46.1 from Q312. Despite the unchanged scores it was ranked 13th instead of 12th (as in the previous quarter) due to the increased attractiveness of the Vietnamese market. It has a fairly balance risk/reward profile which is below the regional average. The attractiveness of Thailand's pharmaceutical sector will continued to be hampered by widespread corruption, poor intellectual property protection and low percapita expenditure on healthcare.
Key Trends And Developments
- In June 2012, US-based BHR Pharma expanded its SyNAPSe clinical trial at 14 sites in Thailand, China and Russia. The trial has 153 participating sites worldwide. The 500th of 1,180 patients is required to conclude the global phase III, multi-centre trial, which was registered in the US at the end of May 2012. SyNAPSe is assessing the effectiveness of BHR-100, a proprietary intravenous progesterone infusion formulation, as a neuroprotective agent to treat traumatic brain injury (TBI) patients.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q4 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Egypt Pharmaceuticals & Healthcare Report Q4 2012
- Turkey Pharmaceuticals & Healthcare Report Q4 2012
- Netherlands Pharmaceuticals & Healthcare Report Q4 2012
- Galectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Latvia Pharmaceuticals & Healthcare Report Q4 2012
- Australia Pharmaceuticals & Healthcare Report Q4 2012
- Taiwan Pharmaceuticals & Healthcare Report Q4 2012
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2012